SCHEMBL13289245

SCHEMBL13289245

Bc1cnn2c(NCc3cccc(NC(=O)Nc4ccc(C)cc4)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 6/20 0.49
▸ GSK3B P49841 5/20 0.49
▸ EPHB4 P54760 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HCRTR1 O43613 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KDR P35968 4/20 0.39
▸ RET P07949 3/20 0.39
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ KCNJ6 P48051 1/20 0.38
▸ KCNJ5 P48544 1/20 0.38
▸ KCNJ3 P48549 1/20 0.38
▸ KCNN3 Q9UGI6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289563 0.94 CDK2 (0.50) CDK2GSK3BEPHB4MEN1KMT2A
SCHEMBL14301776 0.94 CDK2 (0.51) CDK2GSK3BEPHB4KDRRET
SCHEMBL13289340 0.92 CDK2 (0.48) CDK2GSK3BKDRRETKCNJ6
SCHEMBL12954120 0.92 CDK2 (0.49) CDK2GSK3BEPHB4KDRRET
SCHEMBL12954468 0.92 CDK2 (0.51) CDK2GSK3BEPHB4MEN1KMT2A
SCHEMBL13289534 0.91 RET (0.48) CDK2GSK3BCYP1A2CYP3A4CYP2C19
SCHEMBL13289700 0.91 CDK2 (0.47) CDK2GSK3BEPHB4MEN1KMT2A
SCHEMBL13121743 0.91 CDK2 (0.62) CDK2GSK3BKDR
SCHEMBL13289334 0.91 CDK2 (0.49) CDK2GSK3BEPHB4MEN1KMT2A
SCHEMBL13289326 0.90 CDK2 (0.47) CDK2GSK3BEPHB4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback